815pda Phase I/ii Trial of Bnc105p with Everolimus in Metastatic Renal Cell Carcinoma (mrcc): Results of the Randomized Phase Ii Disruptor-1 Trial.
نویسندگان
چکیده
1 City of Hope Medical Center, Duarte, CA, 2 BC Cancer Agency, Vancouver, BC, 3 Univ. of Washington, Seattle, WA, 4 Medical College of South Carolina, Charleston, SC, 5 Mayo Clinic, Rochester, MN, 6 Univ.of Texas Health Science Center, San Antonio, TX, 7 Singapore National Cancer Center, 8 Univ. of New Mexico Cancer Ctr, Albuquerque, NM, 9 Dana Farber Cancer Center, Boston, MA, 10 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 11 Deke-Slayton Cancer Ctr., Webster, TX, 12 Texas Oncology, Fort Worth, TX, 13 Hoosier Cancer Research Network, Indianapolis, IN, 14 Bionomics, Thebarton, SA, Australia, 15 bioCSL, Melbourne, Australia, 16 Charles A. Sammons Cancer Center, Baylor Univ.Medical Center, Dallas, TX
منابع مشابه
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.
PURPOSE BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored in patients with metastatic renal cell carcinoma (mRCC). EXPERIMENTAL DESIGN A phase I study in patients with clear cell mRCC and any prior number of therapies was conducted using a classical 3 + 3 des...
متن کاملCancer Therapy: Clinical A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Purpose: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored inpatientswithmetastatic renal cell carcinoma (mRCC). Experimental Design:Aphase I study in patients with clear cell mRCC and any prior number of therapies was conducted using a classical 3 þ 3 design t...
متن کاملPhase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).
373 Background: BNC105P is a Vascular Disruption Agent (VDA) that destabilizes tubulin polymers leading to selective damage of tumor vasculature, hypoxia and associated tumor necrosis. BNC105P also has a direct anti-proliferative action on cancer cells. Up regulation of the mTOR pathway has been identified as a survival response by the tumor to hypoxic insult. Preclinical investigations demonst...
متن کاملClinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
INTRODUCTION Renal cell carcinoma (RCC) represents 2%-3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target of rapamycin (mTOR) inhibitor everolimus, for the treatment of metastatic RCC (mRCC). AIM The obj...
متن کاملOptimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
Since 2005, an abundance of targeted agents has been approved for the treatment of metastatic renal cell carcinoma (mRCC), without any specification as to what may be the most optimal first-line and second-line sequence. Hence, our objective was to critically examine the evidence supporting the use of first-line and second-line agents in the management of mRCC. Our review suggests that in first...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014